Trial Profile
An Open Label, Multicenter, Phase II Single-arm Trial of AZD9291 in Non-small Cell Lung Cancer (NSCLC) Patients With Uncommon Epidermal Growth Factor Receptor Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Sep 2023 Final overall survival results presented at the 24th World Conference on Lung Cancer.
- 11 Dec 2019 Results published in the Journal of Clinical Oncology
- 19 Mar 2019 New source identified and integrated KCT0003459